Download MendeleyStructure-based Discovery of Cell-Potent Peptidomimetic Inhibitors for Protein N-Terminal Methyltransferase 1.
Chen, D., Dong, G., Deng, Y., Noinaj, N., Huang, R.(2021) ACS Med Chem Lett 12: 485-493
- PubMed: 33738076
- DOI: https://doi.org/10.1021/acsmedchemlett.1c00012
- Primary Citation of Related Structures:
7K3D - PubMed Abstract:
Protein N-terminal methyltransferases (NTMTs) catalyze the methylation of the α-N-terminal amines of proteins starting with an X-P-K/R motif. NTMT1 has been implicated in various cancers and in aging, implying its role as a potential therapeutic target. Through structural modifications of a lead NTMT1 inhibitor, BM30 , we designed and synthesized a diverse set of inhibitors to probe the NTMT1 active site. The incorporation of a naphthyl group at the N-terminal region and an ortho -aminobenzoic amide at the C-terminal region of BM30 generates the top cell-potent inhibitor DC541 , demonstrating increased activity on both purified NTMT1 (IC 50 of 0.34 ± 0.02 μM) and the cellular α-N-terminal methylation level of regulator of chromosome condensation 1 (RCC1, IC 50 value of 30 μM) in human colorectal cancer HT29 cells. Furthermore, DC541 exhibits over 300-fold selectivity to several methyltransferases. This study points out the direction for the development of more cell-potent inhibitors for NTMT1.
Organizational Affiliation:
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue Institute for Drug Discovery, Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States.
